|
101 |
“I didn’t even wonder why I was on the floor” – mixed methods exploration of stroke awareness and help-seeking behaviour at stroke symptom onset
Enthalten in BMC health services research Bd. 24, 2.8.2024, Nr. 1, date:12.2024: 1-12
|
|
|
|
102 |
Identification of a putative molecular subtype of adult-type diffuse astrocytoma with recurrent MAPK pathway alterations
Enthalten in Acta neuropathologica Bd. 148, 18.7.2024, Nr. 1, date:12.2024: 1-5
|
|
|
|
103 |
IDH-mutant astrocytomas with primitive neuronal component have a distinct methylation profile and a higher risk of leptomeningeal spread
Enthalten in Acta neuropathologica Bd. 149, 3.2.2025, Nr. 1, date:6.2025: 1-13
|
|
|
|
104 |
Impact of 18F-FET PET on Target Volume Definition and Tumor Progression of Recurrent High Grade Glioma Treated with Carbon-Ion Radiotherapy
Enthalten in Scientific reports Bd. 8, 8.5.2018, Nr. 1, date:12.2018: 1-13
|
|
|
|
105 |
Impact of delays in initiating postoperative chemoradiation while determining the MGMT promoter-methylation statuses of patients with primary glioblastoma
Enthalten in BMC cancer Bd. 15, 30.7.2015, Nr. 1, date:12.2015: 1-7
|
|
|
|
106 |
Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q – IMPROVE CODEL: the NOA-18 trial
Enthalten in BMC cancer Bd. 22, 13.6.2022, Nr. 1, date:12.2022: 1-12
|
|
|
|
107 |
Incidence, molecular characteristics, and imaging features of “clinically-defined pseudoprogression” in newly diagnosed glioblastoma treated with chemoradiation
Enthalten in Journal of neuro-oncology Bd. 159, 17.7.2022, Nr. 3, date:9.2022: 509-518
|
|
|
|
108 |
Infratentorial IDH-mutant astrocytoma is a distinct subtype
Enthalten in Acta neuropathologica Bd. 140, 10.8.2020, Nr. 4, date:10.2020: 569-581
|
|
|
|
109 |
Integrated genetic analyses of immunodeficiency-associated Epstein-Barr virus- (EBV) positive primary CNS lymphomas
Enthalten in Acta neuropathologica Bd. 146, 26.7.2023, Nr. 3, date:9.2023: 499-514
|
|
|
|
110 |
INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas
Enthalten in Neurological research and practice Bd. 5, 19.10.2023, Nr. 1, date:12.2023: 1-6
|
|
Administration
